TOR Pathway

Sundin
Scientist examining extended-lifespan yeast cells under microscope with rapalink-1 cancer drug vial, illustrating anti-aging breakthrough.
Larawang ginawa ng AI

Next-generation cancer drug shows anti-aging effects in yeast

Iniulat ng AI Larawang ginawa ng AI Fact checked

Researchers at Queen Mary University of London have found that rapalink-1, an experimental TOR inhibitor being investigated for cancer therapy, extends the lifespan of fission yeast. The study also uncovered a role for agmatinases in regulating the TOR pathway through a metabolic feedback loop, suggesting potential links between diet, gut microbes, and aging.

Gumagamit ng cookies ang website na ito

Gumagamit kami ng cookies para sa analytics upang mapabuti ang aming site. Basahin ang aming patakaran sa privacy para sa higit pang impormasyon.
Tanggihan